by TractManager | Feb 12, 2021 | Emerging Technology Report
Evkeeza (evinacumab-dgnb) is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial...
by TractManager | Feb 9, 2021 | Emerging Technology Report
The eXciteOSA Daytime Therapy Device (formerly known as Snoozeal) is a noninvasive electrical muscle stimulation device that delivers electrical pulses through a mouthpiece that sits around the tongue. The system consists of a mouthpiece, a rechargeable control unit...
by TractManager | Feb 8, 2021 | News
These Food and Drug Administration (FDA) developments recently came in:eXciteOSA DeviceOn February 5, 2021, the FDA granted a de novo marketing classification for the eXciteOSA device(Signifier Medical Technologies), a prescription only device intended to reduce...
by TractManager | Feb 4, 2021 | News
The Food and Drug Administration (FDA) reports that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with Xeljanz/Xeljanz XR (tofacitinib; Pfizer) compared with tumor necrosis factor (TNF)...
by TractManager | Feb 4, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on the use of prophylactic negative pressure wound therapy (NPWT) as an alternative to standard primary closure of open abdominal wounds following elective surgery with the goal of preventing surgical site infections...
Recent Comments